Personalized treatment for lung cancer patients with pleural effusion using organoids
Organoid-guided Personalized Treatment of Pleural Effusion
This study is testing whether using lab-grown versions of lung cancer tumors can help doctors choose the best treatment for patients with lung cancer who have fluid buildup in their lungs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Henan Cancer Hospital Government |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT06959173 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on lung cancer patients suffering from pleural effusion by utilizing patient-derived tumor organoids to predict drug sensitivity. The research involves acquiring clinical samples, culturing organoids in vitro, and conducting drug sensitivity tests to guide treatment decisions. By correlating the sensitivity results with clinical medication guidance, the study aims to enhance treatment plans tailored to individual patient needs. The study is conducted at a single center, Henan Cancer Hospital, with a sample capacity of 20 patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and above with malignant pleural effusion and an ECOG score of 0-2.
Not a fit: Patients with a history of malignant tumors in the past 5 years or those with serious complications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for lung cancer patients with pleural effusion.
How similar studies have performed: While the use of organoids for drug sensitivity testing is a growing field, this specific approach for lung cancer and pleural effusion is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: (1)18 years of age and above; (2) Understand and voluntarily sign the informed consent form (ICF), and have good compliance, and can cooperate with diagnosis and follow-up; (3)ECOG score 0-2; (4) Accompanied by malignant pleural effusion; Presence of at least one measurable lesion as assessed by the investigator; Exclusion Criteria: 1. A history of malignant tumor in the past 5 years; 2. Complicated with serious complications, such as uncontrolled heart disease, severe arrhythmia requiring medical treatment, persistent watery diarrhea, etc.; 3. Pregnant or lactating female patients; Patients deemed unsuitable for participation in this study.
Where this trial is running
Zhengzhou, Henan
- Henan cancer hospital — Zhengzhou, Henan, China (Recruiting)
Study contacts
- Study coordinator: Qiming Wang
- Email: qimingwang1006@126.com
- Phone: 13783590691
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.